According to a 2025 study published in the New England Journal of Medicine, SURMOUNT-5 enrolled 751 adults with obesity (BMI 30 or higher) who did not have type 2 diabetes and followed them for 72 weeks [1]. Participants were randomized to tirzepatide (titrated up to 10 or 15 mg) or semaglutide 2.4 mg. Tirzepatide produced an average body weight reduction of 20.2%, compared to 13.7% with semaglutide, a difference of 6.5 percentage points (p<0.001). Waist circumference also shrank more with tirzepatide: 18.4 cm vs 13.0 cm.

That finding aligns closely with the broader meta-analytic literature. A 2025 systematic review and meta-analysis published in the Journal of Clinical Medicine Research pooled data from seven studies covering 142,811 participants and found that tirzepatide produced significantly greater weight loss than semaglutide, with a mean difference of 4.23 percentage points overall [2]. At doses above 10 mg, the gap widened to a mean difference of 6.50 percentage points (95% CI: 5.93 to 7.08; p<0.01).

The advantage holds even when you look only at people who already have type 2 diabetes, a population that historically loses less weight on any intervention. A 2025 meta-analysis published in Endocrinology, Diabetes and Metabolism examined 28,827 participants with type 2 diabetes and found tirzepatide produced 4.84 kg more weight loss than semaglutide on average (95% CI: 3.47 to 6.21 kg) [3]. In percentage terms, that translated to roughly 11.4% with tirzepatide versus 7.3% with semaglutide.

Real-world data paint a consistent picture. A 2024 retrospective cohort study published in JAMA Internal Medicine matched 18,386 patients treated with either drug in routine clinical care and followed them for 12 months [6]. Tirzepatide users lost an average of 15.3% of body weight, compared to 8.3% among semaglutide users, a gap of nearly 7 percentage points. The odds of achieving clinically meaningful thresholds were substantially higher with tirzepatide: patients were 1.76 times more likely to reach 5% loss, 2.54 times more likely to reach 10%, and 3.24 times more likely to reach 15%. Both groups had similar discontinuation rates, around 53% to 55%, which is a useful reminder that tolerability and adherence remain challenges regardless of which drug you choose.

Side Effects and Tolerability: What the Trials Actually Found

The most common side effects of both drugs involve the gastrointestinal tract. Nausea, diarrhea, vomiting, and constipation are reported by a meaningful share of users, and they tend to be most noticeable during dose escalation. The reassuring news is that these effects are generally mild to moderate, tend to improve over time, and rarely require stopping treatment.

A 2024 pooled analysis of the entire SURPASS clinical trial program for tirzepatide, covering five Phase 3 studies, found that nausea occurred in 12 to 24% of tirzepatide-treated participants, diarrhea in 12 to 22%, and vomiting in 2 to 13% [8]. Crucially, a mediation analysis in that same paper found that gastrointestinal adverse events accounted for less than 6% of tirzepatide's weight loss advantage over comparators. In other words, tirzepatide is not simply causing people to eat less because they feel sick: the weight loss is a genuine pharmacological effect driven by appetite regulation and metabolic changes.

The SURPASS-2 trial provides one of the clearest direct safety comparisons available prior to SURMOUNT-5. Clinical trials show that nausea rates were broadly comparable between all three tirzepatide doses and semaglutide 1 mg: 17 to 22% with tirzepatide versus 18% with semaglutide; diarrhea was 13 to 16% versus 12% [4]. The indirect treatment comparison literature also suggests that higher doses of tirzepatide (10 and 15 mg) may produce fewer gastrointestinal events than semaglutide 2.4 mg, though these findings come from indirect comparisons and should be interpreted with appropriate caution [7].

Discontinuation due to gastrointestinal events is worth flagging specifically. In the STEP 1 semaglutide trial, 4.5% of participants stopped treatment because of GI side effects [5]. In SURMOUNT-5, GI events were described as mild to moderate in both groups, and the overall tolerability picture was considered comparable [1]. Across both drugs, slower dose escalation and taking injections with food can help manage these side effects in practice.

Beyond the gut, both drugs carry a class warning about thyroid C-cell tumors based on rodent studies, though a causal link in humans has not been established. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Neither drug is currently recommended during pregnancy.

Who Should Choose Tirzepatide vs Semaglutide

If the efficacy data consistently favor tirzepatide, you might wonder why anyone would still choose semaglutide. The answer involves a mix of practical, medical, and personal factors that matter just as much as trial averages.

Tirzepatide may be the stronger option if your primary goal is maximum weight loss and your prescriber agrees you are a candidate for the higher doses. The SURMOUNT-5 data show the largest advantages at the 10 and 15 mg doses, so the full benefit requires tolerating dose escalation [1]. People with type 2 diabetes have additional reasons to consider tirzepatide: the drug has robust evidence for HbA1c reduction, and its dual GIP/GLP-1 mechanism appears to offer complementary benefits for blood sugar control that go beyond what semaglutide achieves at comparable doses [4].

Semaglutide has a longer track record and broader clinical experience. It has been in use since 2021 at the obesity dose, and prescribers have accumulated more real-world familiarity with its dosing patterns, side effect profiles, and long-term tolerability. For people who have tried semaglutide and responded well, the incremental benefit of switching to tirzepatide may not justify the disruption. Semaglutide also has cardiovascular outcome data from the SELECT trial showing a 20% reduction in major adverse cardiovascular events in people with established cardiovascular disease. Both medications can affect body composition; for guidance on preserving lean mass during treatment, see our guide to preventing muscle loss on GLP-1 medications. Cardiovascular outcome trial data for tirzepatide in people without diabetes are still emerging.

Individual tolerability is another consideration. Some people find that one drug suits them better than the other, and there is no reliable way to predict in advance who will respond best to which mechanism. If you have had a poor experience with one drug, switching to the other is a reasonable clinical conversation to have with your doctor.

Access and cost also shape real-world choices in meaningful ways. Both drugs have faced supply shortages, prior authorization hurdles, and high out-of-pocket costs in markets where insurance coverage is limited. Your practical access to one drug over the other may ultimately be the deciding factor, regardless of what the trial averages show.

Practical Guide: Costs, Access, and Dosing

Understanding how each drug is prescribed and what you can expect from the dosing schedule helps you set realistic expectations before you start.

Semaglutide 2.4 mg (Wegovy) starts at 0.25 mg once weekly for the first four weeks, then increases by 0.25 mg every four weeks until reaching the 2.4 mg maintenance dose at week 17. The escalation is gradual by design: moving up slowly gives your body time to adapt and reduces the intensity of gastrointestinal side effects. Tirzepatide (Zepbound) follows a similar principle, starting at 2.5 mg weekly for four weeks, then increasing by 2.5 mg every four weeks up to a maximum of 15 mg. Reaching the highest dose therefore takes roughly 20 weeks. An oral semaglutide formulation also exists for those who prefer to avoid injections (read our full review of oral semaglutide).

Both drugs are approved in the United States and several other countries for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. Prescribers will typically confirm these criteria before initiating treatment and will monitor weight, metabolic markers, and tolerability at follow-up visits.

List prices for both medications in the US currently run above $1,000 per month without insurance coverage, though manufacturer savings programs, prior authorization, and insurance formulary coverage can reduce out-of-pocket costs significantly for eligible patients. Both drugs require refrigerated storage prior to first use. Auto-injector pens make self-administration straightforward for most people, and your prescriber or pharmacist can walk you through the injection technique at your first prescription. Consistent daily dosing and taking injections with food can improve both tolerability and absorption.

Frequently Asked Questions

Is tirzepatide really that much better than semaglutide for weight loss?

The clinical evidence is consistent across multiple study types. The SURMOUNT-5 head-to-head trial found a 6.5 percentage point difference in body weight reduction favoring tirzepatide at 72 weeks [1]. A large meta-analysis of over 142,000 participants found a mean difference of about 4.2 percentage points across all doses, widening to 6.5 percentage points at doses above 10 mg [2]. The advantage is real, but individual responses vary, and some people do very well on semaglutide.

Do tirzepatide and semaglutide have the same side effects?

The side effect profiles are broadly similar, with gastrointestinal symptoms being the most common for both drugs. Nausea, diarrhea, vomiting, and constipation are reported in both groups and tend to peak during dose escalation before improving [8]. A pooled analysis of tirzepatide trials found that GI events account for less than 6% of its weight loss advantage, meaning the extra weight loss is not simply because tirzepatide makes people feel too sick to eat [8].

Can I switch from semaglutide to tirzepatide?

Switching between these medications is clinically feasible and happens in practice, but it should be done under medical supervision. Your prescriber will want to consider your current dose, how you have tolerated semaglutide, and what dose of tirzepatide to start you on. There is no standardized cross-over protocol, so individual guidance from your healthcare provider is essential.

Which drug is better if I have type 2 diabetes?

Both drugs are approved for type 2 diabetes management as well as weight loss. The SURPASS-2 trial and a large T2D-specific meta-analysis both found that tirzepatide produced greater weight reduction and HbA1c improvement than semaglutide in people with type 2 diabetes [3][4]. Your prescriber will factor in your overall diabetes management plan, other medications you take, and cardiovascular risk profile when making a recommendation.

How long do I need to stay on these medications?

Both tirzepatide and semaglutide are treatments for a chronic condition, not short-term interventions. Clinical trial data and real-world follow-up consistently show that weight regain occurs when either drug is stopped, which reflects the underlying biology of obesity rather than a failure of the medication. Long-term use under medical supervision is the current standard approach, and discontinuation should always be discussed with your healthcare provider.

References

[1] Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2416394

[2] Bin Aamir A, et al. Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine Research. 2025. DOI: 10.14740/jocmr6231

[3] Wen Y, et al. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis. Endocrinology, Diabetes and Metabolism. 2025. DOI: 10.1002/edm2.70045

[4] Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2107519

[5] Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2032183

[6] Rodriguez PJ, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine. 2024. DOI: 10.1001/jamainternmed.2024.2525

[7] Singh G, et al. Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5-15 mg in obesity: A systematic review of Phase 3 clinical trials. Diabetes and Metabolic Syndrome. 2025. DOI: 10.1016/j.dsx.2025.103212

[8] Patel H, et al. Gastrointestinal adverse events and weight reduction in tirzepatide in SURPASS clinical trials. Diabetes, Obesity and Metabolism. 2024. DOI: 10.1111/dom.15333

This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.